AUD 0.1
(-2.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 | 4.55 Million AUD | -50.18% |
2023 | 9.14 Million AUD | 88.25% |
2022 | 4.85 Million AUD | -13.29% |
2021 | 5.6 Million AUD | -14.32% |
2020 | 6.53 Million AUD | 67.59% |
2019 | 3.9 Million AUD | 81.1% |
2018 | 2.15 Million AUD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q4 | 2.25 Million AUD | 0.0% |
2024 FY | 4.55 Million AUD | -50.18% |
2024 Q2 | 2.29 Million AUD | 0.0% |
2023 FY | 9.14 Million AUD | 88.25% |
2023 Q2 | 3.73 Million AUD | 0.0% |
2023 Q4 | 5.41 Million AUD | 0.0% |
2022 Q4 | 2.04 Million AUD | 0.0% |
2022 FY | 4.85 Million AUD | -13.29% |
2022 Q2 | 2.81 Million AUD | 0.0% |
2021 Q4 | 2.9 Million AUD | 0.0% |
2021 FY | 5.6 Million AUD | -14.32% |
2021 Q2 | 2.73 Million AUD | 0.0% |
2020 FY | 6.53 Million AUD | 67.59% |
2020 Q4 | 4.2 Million AUD | 0.0% |
2020 Q2 | 2.24 Million AUD | 0.0% |
2019 Q2 | 1.58 Million AUD | 100.0% |
2019 Q4 | 1.31 Million AUD | 0.0% |
2019 FY | 3.9 Million AUD | 81.1% |
2019 Q1 | 794.8 Thousand AUD | 0.0% |
2018 FY | 2.15 Million AUD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
EZZ Life Science Holdings Limited | 39.57 Million AUD | 88.49% |
Anatara Lifesciences Ltd | 710.21 Thousand AUD | -541.377% |
Zelira Therapeutics Limited | 5.94 Million AUD | 23.423% |
Biome Australia Limited | 7.91 Million AUD | 42.421% |
Patrys Limited | 4.93 Million AUD | 7.665% |
Orthocell Limited | 15.36 Million AUD | 70.362% |
Imugene Limited | 135.09 Million AUD | 96.628% |
Noxopharm Limited | 7 Million AUD | 34.928% |
PYC Therapeutics Limited | 60.91 Million AUD | 92.522% |
Chimeric Therapeutics Limited | 19.76 Million AUD | 76.956% |
Prescient Therapeutics Limited | 10.89 Million AUD | 58.205% |
Proteomics International Laboratories Limited | 892.14 Thousand AUD | -410.587% |
Cynata Therapeutics Limited | 11.12 Million AUD | 59.049% |
CSL Limited | 7.56 Billion AUD | 99.94% |
Arovella Therapeutics Limited | 10.78 Million AUD | 57.765% |
Bio-Gene Technology Limited | 2.76 Million AUD | -64.982% |
Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 85.445% |
Starpharma Holdings Limited | 22.81 Million AUD | 80.035% |
Nanollose Limited | 12.5 Thousand AUD | -36338.429% |
Memphasys Limited | 3.67 Million AUD | -23.836% |
Invex Therapeutics Ltd | 3.34 Million AUD | -36.142% |
NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -131.789% |
Amplia Therapeutics Limited | 8.43 Million AUD | 46.001% |
Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -656.899% |
Island Pharmaceuticals Limited | 4.12 Million AUD | -10.419% |
Race Oncology Limited | 14.77 Million AUD | 69.16% |
Telix Pharmaceuticals Limited | 269.26 Million AUD | 98.308% |
Dimerix Limited | 25.64 Million AUD | 82.236% |
PharmAust Limited | 6.65 Million AUD | 31.573% |
Immutep Limited | 42.87 Million AUD | 89.376% |
Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 91.91% |
Alterity Therapeutics Limited | 23.4 Million AUD | 80.539% |
BTC Health Limited | -1.03 Million AUD | 538.449% |
Acrux Limited | 8.55 Million AUD | 46.723% |
Neuren Pharmaceuticals Limited | 32.69 Million AUD | 86.069% |
Biotron Limited | 5.11 Million AUD | 10.87% |
Tissue Repair Ltd | 6.66 Million AUD | 31.674% |
AdAlta Limited | 6.76 Million AUD | 32.711% |
Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1422.307% |
Hexima Limited | 1 Million AUD | -351.566% |
AnteoTech Limited | 12.18 Million AUD | 62.623% |
Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 93.003% |
Recce Pharmaceuticals Ltd | 21.68 Million AUD | 78.993% |
Avecho Biotechnology Limited | 4.54 Million AUD | -0.215% |
Actinogen Medical Limited | 22.77 Million AUD | 79.995% |
Immuron Limited | 9.13 Million AUD | 50.151% |
Argenica Therapeutics Limited | 8.26 Million AUD | 44.914% |